Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice

European Neuropsychopharmacology

Volumn 17, Issue 2, 2007, Pages 145-155

  Young, Jared W ^a   Crawford, Nicola ^a   Kelly, John S ^a   Kerr, Lorraine E ^a   Marston, Hugh M ^a   Spratt, Christopher ^a   Finlayson, Keith ^a   Sharkey, John ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Alpha7 transgenic mice or schizophrenia; Attention; Nicotinic; Working memory

Indexed keywords

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OLFACTORY DISCRIMINATION; PRIORITY JOURNAL; RECEPTOR DENSITY; TASK PERFORMANCE; TRANSGENIC MOUSE; WILD TYPE; WORKING MEMORY;

ACONITINE; ALKALOIDS; ANIMALS; ANIMALS, NEWBORN; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AZOCINES; BEHAVIOR, ANIMAL; CHOICE BEHAVIOR; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, KNOCKOUT; NICOTINIC ANTAGONISTS; PROTEIN BINDING; QUINOLIZINES; REACTION TIME; RECEPTORS, NICOTINIC; TRITIUM;

EID: 33751334112     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.03.008     Document Type: Article

References (75)

1. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., and Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry 32 (1992) 607-616
2. Arendash G.W., Sengstock G.J., Sanberg P.R., and Kem W.R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674 (1995) 252-259
3. Bednar I., Paterson D., Marutle A., Pham T.M., Svedberg M., Hellstrom-Lindahl E., Mousavi M., Court J., Morris C., Perry E., Mohammed A., Zhang X., and Nordberg A. Selective nicotinic receptor consequences in APPSWE transgenic mice. Mol. Cell. Neurosci. 20 (2002) 365
4. 125I]-alpha-bungarotoxin binding in human postmortem brain. J. Comp. Neurol. 387 (1997) 385-398
5. Briggs C.A., Anderson D.J., Brioni J.D., Buccafusco J.J., Buckley M.J., Campbell J.E., Decker M.W., Donnelly-Roberts D., Elliott R.L., Gopalakrishnan M., Holladay M.W., Hui Y.H., Jackson W.J., Kim D.J., Marsh K.C., O'Neill A., Prendergast M.A., Ryther K.B., Sullivan J.P., and Arneric S.P. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. 57 (1997) 231-241
6. Chudasama Y., and Robbins T.W. Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task, implications for schizophrenia. Psychopharmacology (Berl.) 174 (2004) 86-98
7. Cilia J., Cluderay J.E., Robbins M.J., Reavill C., Southam E., Kew J.N., and Jones D.N. Reversal of isolation-rearing-induced PPI deficits by an alpha 7 nicotinic receptor agonist. Psychopharmacology 182 (2005) 214-219
8. Cornblatt B.A., and Keilp J.G. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr. Bull. 20 (1994) 31-46
9. Cullum C.M., Harris J.G., Waldo M.C., Smernoff E., Madison A., Nagamoto H.T., Griffith J., Adler L.E., and Freedman R. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr. Res. 10 (1993) 131-141
10. 3H]methyllycaconitine, a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38 (1999) 679-690
11. Dépatie L., O'Driscoll G.A., Holahan A.L., Atkinson V., Thavundayil J.X., Kin N.N., and Lal S. Nicotine and behavioral markers of risk for schizophrenia, a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 27 (2002) 1056-1070
12. Dudchenko P.A., Wood E.R., and Eichenbaum H. Neurotoxic hippocampal lesions have no effect on odor span and little effect on odor recognition memory but produce significant impairments on spatial span, recognition, and alternation. J. Neurosci. 20 (2000) 2964-2977
13. Franceschini D., Paylor R., Broide R., Salas R., Bassetto L., Gotti C., and De Biasi M. Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. Brain Res. Mol. Brain Res. 98 (2002) 29-40
14. Freedman R., and Leonard S. Genetic linkage to schizophrenia at chromosome 15q14. Am. J. Med. Genet. 105 (2001) 655-657
15. Freedman R., Hall M., Adler L.E., and Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry 38 (1995) 22-33
16. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., and Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. U. S. A 94 (1997) 587-592
17. Freedman R., Ross R., Leonard S., Myles-Worsley M., Adams C.E., Waldo M., Tregellas J., Martin L., Olincy A., Tanabe J., Kisley M.A., Hunter S., and Stevens K.E. Early biomarkers of psychosis. Dialogues Clin. Neurosci. 7 (2005) 17-29
18. Fuchs S., Perl O., Ilani T., and Strous R.D. S.15.04 The α7 nicotinic receptor as a potential peripheral marker for schizophrenia. Eur. Neuropsychopharmacol. 14 (2004) S141
19. Gommans J., Stolerman I.P., and Shoaib M. Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice. Neuropharmacology 39 (2000) 2840-2847
20. Gothelf D., Soreni N., Nachman R.P., Tyano S., Hiss Y., Reiner O., and Weizman A. Evidence for the involvement of the hippocampus in the pathophysiology of schizophrenia. Eur. Neuropsychopharmacol. 10 (2000) 389-395
21. Gotti C., Carbonnelle E., Moretti M., Zwart R., and Clementi F. Drugs selective for nicotinic receptor subtypes, a real possibility or a dream?. Behav. Brain Res. 113 (2000) 183-192
22. Greco B., Invernizzi R.W., and Calri M. Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268. Psychopharmacology 179 (2005) 68-76
23. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153 (1996) 321-330
24. Grottick A.J., and Higgins G.A. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav. Brain Res. 117 (2000) 197-208
25. Grottick A.J., Wyler R., and Higgins G.A. The alpha4beta2 agonist SIB 1765F, but not the alpha7 agonist AR-R 17779, cross-sensitises to the psychostimulant effects of nicotine. Psychopharmacology (Berl.) 150 (2000) 233-236
26. Grottick A.J., Haman M., Wyler R., and Higgins G.A. Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. Neuropsychopharmacology 28 (2003) 880-887
27. Hahn B., Shoaib M., and Stolerman I.P. Nicotine-induced enhancement of attention in the five-choice serial reaction time task, the influence of task demands. Psychopharmacology (Berl.) 162 (2002) 129-137
28. Hahn B., Sharples C.G., Wonnacott S., Shoaib M., and Stolerman I.P. Attentional effects of nicotinic agonists in rats. Neuropharmacology 44 (2003) 1054-1067
29. Hajos M., Hurst R.S., Hoffmann W.E., Krause M., Wall T.M., Higdon N.R., and Groppi V.E. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther. 312 (2005) 1213-1222
30. Hashimoto K., Masaomi I., Freedman R., and Stevens K. Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of α7 nicotinic acetylcholine receptors. Psychopharmacology 183 (2005) 13-19
31. Jacobsen L.K., D'Souza D.C., Mencl W.E., Pugh K.R., Skudlarski P., and Krystal J.H. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol. Psychiatry 55 (2004) 850-858
32. Jones D.N., and Higgins G.A. Effect of scopolamine on visual attention in rats. Psychopharmacology (Berl.) 120 (1995) 142-149
33. Keller J.J., Keller A.B., Bowers B.J., and Wehner J.M. Performance of alpha7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signal nose poke task. Behav. Brain Res. 162 (2005) 143-152
34. Kem W.R. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease, studies with DMXBA (GTS-21). Behav. Brain Res. 113 (2000) 169-181
35. Kitagawa H., Takenouchi T., Azuma R., Wesnes K.A., Kramer W.G., Clody D.E., and Burnett A.L. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28 (2003) 542-551
36. Koike K., Hashimoto K., Takai N., Shimizu E., Komatsu N., Watanabe H., Nakazato M., Okamura N., Stevens K.E., Freedman R., and Iyo M. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr. Res. 76 (2005) 67-72
37. Langley J.N. On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and curare. J. Physiol. (Lond.) 33 (1905) 374-413
38. Lena C., and Changeux J.P. The role of beta 2-subunit-containing nicotinic acetylcholine receptors in the brain explored with a mutant mouse. Ann. N.Y. Acad. Sci. 868 (1999) 611-616
39. Le Novere N., Corringer P.J., and Changeux J.P. The diversity of subunit composition in nAChRs, evolutionary origins, physiologic and pharmacologic consequences. J. Neurobiol. 53 (2002) 447-456
40. Levin E.D. Nicotinic receptor subtypes and cognitive function. J. Neurobiol. 53 (2002) 633-640
41. Levin E.D., Conners C.K., Silva D., Hinton S.C., Meck W.H., March J., and Rose J.E. Transdermal nicotine effects on attention. Psychopharmacology (Berl.) 140 (1998) 135-141
42. Levin E.D., Bettegowda C., Blosser J., and Gordon J. AR-R17779, an alpha7 nicotinic agonist, improves learning and memory in rats. Behav. Pharmacol. 10 (1999) 675-680
43. Luntz-Leybman V., Bickford P.C., and Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 587 (1992) 130-136
44. Maemoto T., Finlayson K., Olverman H.J., Akahane A., Horton R.W., and Butcher S.P. Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists. Br. J. Pharmacol. 122 (1997) 1202-1208
45. Mancuso G., Warburton D.M., Melen M., Sherwood N.M., and Tirelli E. Selective effects of nicotine on attentional processes. Psychopharmacology 146 (1999) 199-204
46. Marks M.J., Stitzel J.A., Romm E., Wehner J.M., and Collins A.C. Nicotinic binding sites in rat and mouse brain, comparison of acetylcholine, nicotine, and alpha-bungarotoxin. Mol. Pharmacol. 30 (1986) 427-436
47. Marks M.J., Smith K.W., and Collins A.C. Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. J. Pharmacol. Exp. Ther. 285 (1998) 377-386
48. Martin L.F., Kem W.R., and Freedman R. Alpha-7 nicotinic receptor agonists, potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl.) 174 (2004) 54-64
49. Muir J.L., Bussey T.J., Everitt B.J., and Robbins T.W. Dissociable effects of AMPA-induced lesions of the vertical limb diagonal band of Broca on performance of the 5-choice serial reaction time task and on acquisition of a conditional visual discrimination. Behav. Brain Res. 82 (1996) 31-44
50. Newhouse P.A., Potter A., and Singh A. Effects of nicotinic stimulation on cognitive performance. Curr. Opin. Pharmacol. 4 (2004) 36-46
51. O'Neill H.C., Rieger K., Kem W.R., and Stevens K.E. DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology (Berl.) 169 (2003) 332-339
52. Orr-Urtreger A., Goldner F.M., Saeki M., Lorenzo I., Goldberg L., De Biasi M., Dani J.A., Patrick J.W., and Beaudet A.L. Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J. Neurosci. 17 (1997) 9165-9171
53. 3H]-cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol. 39 (1991) 9-12
54. Parasuraman R. The Attentive Brain (1998), MIT Press, London, England
55. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., Fuxe K., and Changeux J.P. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391 (1998) 173-177
56. Robbins T.W. The 5-choice serial reaction time task, behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl.) 163 (2002) 362-380
57. Robbins T.W. Synthesizing schizophrenia: a bottom-up, symptomatic approach. Schizophr. Bull. 31 4 (2005) 854-864
58. Ross S.A., Wong J.Y., Clifford J.J., Kinsella A., Massalas J.S., Horne M.K., Scheffer I.E., Kola I., Waddington J.L., Berkovic S.F., and Drago J. Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J. Neurosci. 20 (2000) 6431-6441
59. Rossi F.M., Pizzorusso T., Porciatti V., Marubio L.M., Maffei L., and Changeux J.P. Requirement of the nicotinic acetylcholine receptor beta 2 subunit for the anatomical and functional development of the visual system. Proc. Natl. Acad. Sci. U. S. A 98 (2001) 6453-6458
60. Sambrook J., and Russell D.W. Molecular Cloning, A Laboratory Manual. 3rd ed. (2001), Cold Spring Harbor Laboratory Press, New York
61. Sharma T., and Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr. Clin. North Am. 26 (2003) 25-40
62. Simosky J.K., Stevens K.E., Kem W.R., and Freedman R. Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol. Psychiatry 50 (2001) 493-500
63. Simosky J.K., Stevens K.E., Adler L.E., and Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl.) 165 (2003) 386-396
64. Stevens K.E., and Wear K.D. Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol. Biochem. Behav. 57 (1997) 869-874
65. Stevens K.E., Freedman R., Collins A.C., Hall M., Leonard S., Marks M.J., and Rose G.M. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15 (1996) 152-162
66. Stevens K.E., Kem W.R., Mahnir V.M., and Freedman R. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl.) 136 (1998) 320-327
67. Stolerman I.P., Chamberlain S., Bizarro L., Fernandes C., and Schalkwyk L. The role of nicotinic receptor a7 subunits in nicotine discriminations. Neuropharmacology 46 (2004) 363-371
68. Tatsumi R., Fujio M., Satoh H., Katayama J., Takanashi S., Hashimoto K., and Tanaka H. Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3′-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5 ′-[1′,3′]oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligand. J. Med. Chem. 48 (2005) 2678-2686
69. Turchi J., and Sarter M. Cortical cholinergic inputs mediate processing capacity: effects of 192 IgG-saporin-induced lesions on olfactory span performance. Eur. J. Neurosci. 12 (2000) 4505-4514
70. Van Kampen M., Selbach K., Schneider R., Schiegel E., Boess F., and Schreiber R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl.) 172 (2004) 375-383
71. Watkins S.S., Epping-Jordan M.P., Koob G.F., and Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol. Biochem. Behav. 62 (1999) 743-751
72. Whiteaker P., Davies A.R., Marks M.J., Blagbrough I.S., Potter B.V., Wolstenholme A.J., Collins A.C., and Wonnacott S. An autoradiographic study of the distribution of binding sites for the novel alpha7-selective nicotinic radioligand [3H]-methyllycaconitine in the mouse brain. Eur. J. Neurosci. 11 (1999) 2689-2696
73. Young J.W., Amet L.E., Asada T., Spratt C., Marston H.M., Kelly J.S., and Sharkey J. Mice over-expressing human caspase-3 exhibit cognitive deficits in an olfactory working memory task. FENS Abstr. 1 (2002) A151.20
74. Young J.W., Finlayson K., Spratt C., Marston H.M., Crawford N., Kelly J.S., and Sharkey J. Nicotine improves sustained attention in mice, evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 29 (2004) 891-900
75. Zoli M., Picciotto M.R., Ferrari R., Cocchi D., and Changeux J.P. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J. 18 (1999) 1235-1244